D. E. Smith

Perspective on the inherent safety of LMR's

R. P. Omberg, A. Padilla, L. D. O'Dell, 1985 .

Efavirenz and chronic neuropsychiatric symptoms: a cross‐sectional case control study

D. E. Smith, T. Rihs, J. Post, 2006, HIV medicine.

Anticoagulant effects of the selective factor XA inhibitors tick anticoagulant peptide and antistasin in the APTT assay are determined by the relative rate of prothrombinase inhibition.

D. E. Smith, C. Dunwiddie, G. Vlasuk, 1991, Thrombosis research.

A randomized, double‐blind, placebo‐controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection

D. E. Smith, M. Youle, B. Gazzard, 2001, HIV medicine.

Steady‐state pharmacokinetics of delavirdine in HIV‐positive patients: Effect on erythromycin breath test

D. E. Smith, G. Amidon, P. Watkins, 1997, Clinical pharmacology and therapeutics.

Multi-centre field evaluation of the performance of the Trinity Biotech Uni-Gold HIV 1/2 rapid test as a first-line screening assay for gay and bisexual men compared with 4th generation laboratory immunoassays.

D. E. Smith, R. Guy, P. Read, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Factors associated with unprotected anal intercourse between HIV-positive men and regular male partners in a Sydney cohort

D. E. Smith, M. Batterham, S. Jeganathan, 2009, International journal of STD & AIDS.